Head to Head Impact of Margin, Ischemia, Complications, Score Versus a Novel Trifecta Score on Oncologic and Functional Outcomes After Robotic-assisted Partial Nephrectomy: Results of a Multicenter Series by Anceschi, U. et al.
EUF-956; No. of Pages 9Head to Head Impact of Margin, Ischemia, Complications, Score
Versus a Novel Trifecta Score on Oncologic and Functional
Outcomes After Robotic-assisted Partial Nephrectomy:
Results of a Multicenter Series
Umberto Anceschi a,*, Maria Consiglia Ferriero a, Gabriele Tuderti a, Aldo Brassetti a,
Riccardo Bertolo b, Umberto Capitanio c, Alessandro Larcher c, Juan Garisto b,
Alessandro Antonelli d, Alexander Mottrie e, Andrea Minervini f, Paolo Dell’Oglio e,
Alessandro Veccia d, Daniele Amparore g, Andrea Mari f, Francesco Porpiglia g,
Francesco Montorsi c, Jihad Kaouk b, Marco Carini f, Riccardo Autorino h,
Michele Gallucci i, Giuseppe Simone a
aDepartment of Urology, Regina Elena National Cancer Institute, Rome, Italy; bDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland
Clinic, Cleveland, OH, USA; cUnit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), San Raffaele Hospital IRCCS, Milan, Italy;
dDepartment of Urology, Spedali Civili di Brescia, Brescia, Italy; eDepartment of Urology, OLV Hospital, Aalst, Belgium; fDepartment of Urology, Careggi
Hospital, University of Florence, Florence, Italy; gDivision of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; hDivision of
Urology, Department of Surgery, Virginia Commonwealth University Health System, Richmond, VA, USA; iDepartment of Urology, Policlinico Umberto I, “La
Sapienza” University, Rome, Italy
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 9 ) X X X – X X X
ava i lable at www.sc iencedirect .com
journa l homepage: www.europea nurology.com/eufocus
Article info
Article history:











Background: There is a paucity of data describing the ability of margin, ischemia,
complications, score (MIC) and trifecta in predicting long-term outcomes of robotic-
assisted partial nephrectomy (RAPN).
Objective: To compare a novel trifecta (negative margins, no significant complications,
and perioperative estimated glomerular filtration rate [eGFR] decrease 30%) versus
standard MIC as predictors of oncologic and functional results in a large series of RAPNs.
Design, setting, and participants: : Between 2009 and 2019, a multicenter dataset was
queried for patients with nonmetastatic renal masses who underwent RAPN at eight
participating institutions.
Intervention: RAPN.
Outcome measurements and statistical analysis: MIC and trifecta achievement were
determined for the overall cohort and a subgroup undergoing off-clamp RAPN (ocRAPN),
respectively. The overall survival (OS), recurrence-free survival (RFS), and new onset of
end-stage renal disease (ESRD; defined as eGFR <30 ml/min) probabilities were assessed
by the Kaplan-Meier method. Cox regression analyses were used to identify predictors of
OS, RFS, and ESRD. For all analyses, two-sided p < 0.05 was considered significant.
Results and limitations: Out of 1807 patients, MIC and trifecta were achieved in 71.1% (n
= 1285) and 82.6% (n = 1492), respectively, and once restricted to the ocRAPN cohort, in
95.6% (n = 625) and 81.6% (n = 534), respectively. On Kaplan-Meier analysis, both MIC
and trifecta achievement predicted higher OS and lower ESRD probabilities (all
p < 0.014), while only trifecta achievement was a predictor of RFS probabilities (p =
0.009). On multivariab
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independently, while trifecta achievement was an independent predictor of higher
OS (hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.18–0.86; p = 0.019) and lower
ESRD development probabilities (HR 0.32, 95% CI 0.15–0.72; p = 0.005).
Conclusions: Trifecta, initially described as comprehensive measures of periopera-
tive outcomes, needs to stand the test of time. Compared with MIC, the recent trifecta
was an independent predictor of clinically significant endpoints, namely, survival and
ESRD development probabilities.
Patient summary: Our novel trifecta represents a reliable method for estimating
survival and development of end-stage renal disease after robotic-assisted partial
nephrectomy.
© 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Since its first description, the concept of “trifecta” for stan-
dardizing the results of robotic-assisted partial nephrec-
tomy (RAPN) in a single scoring system has become a
convenient tool to assess perioperative outcomes and opti-
mize reproducibility between series [1,2]. In recent years,
alternative definitions and refinements of the original tri-
fecta have been proposed; however, the extensive variabil-
ity used across authors to evaluate acute kidney injury (AKI)
may have had a significant impact on reported outcomes
[3,4]. With a lack of agreement on standard definition of
main surgical factors, it is very hard to measure trifecta
achievement objectively, with the consequent risk of unre-
liable description of results [5].
To date, margin, ischemia, complications, score (MIC)
and the original trifecta proposed by Khalifeh et al [2] are
the most widely used standardized reporting system for
evaluating outcomes of RAPN [6,7]. However, reproducibil-
ity of these tools for off-clamp procedures remains ques-
tionable; moreover, their predictive role in both oncologic
and functional outcomes has not directly been compared or
explored in large series [8]. In this context, we have
described recently a novel comprehensive trifecta for RAPN
replacing the warm ischemia time (WIT) with perioperative
estimated glomerular filtration rate (DeGFR) variations, in
order to include clampless procedures also [9,10].
Herein, we performed a head-to-head comparison of our
novel trifecta definition with the standard MIC in a multi-
center series of RAPN. The aim of this study was to assess
and compare the ability of these scoring systems in pre-
dicting oncologic outcomes and the risk of progression to
ESRD after surgery.
2. Patients and methods
This observational, retrospective, multicenter study received
internal review board approval at each contributing center.
Out of 1949 cases, patients with tumors in solitary kidneys (n
= 45), those with multiple renal masses (n = 12), and cases
with missing data (n = 85) were excluded from the analysis;
1807 patients who underwent RAPN for cT1-cT2 renal masses
between September 2006 and April 2020 at eight participat-
ing institutions were included in the analysis. Inclusion cri-
teria included diagnosis with a single, organ-confined, con-
trast-enhancing, cT1-cT2 nonmetastatic renal tumor.Please cite this article in press as: Anceschi U, et al. Head to Head Im
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were preoperatively evaluated with a computed tomography
scan or magnetic resonance imaging.
Demographic, perioperative, pathologic, oncologic, and
functional outcome data were gathered in a single custom-
ized dataset. Evaluated preoperative clinical and demo-
graphic characteristics included age, gender, race, body
mass index, American Society of Anesthesiologists (ASA)
score, baseline estimated glomerular filtration rate (eGFR;
ml/min/1.73 m2), baseline chronic kidney disease (CKD)
stage, clinical tumor size, and RENAL nephrometry score.
Perioperative variables included postoperative eGFR,
DeGFR, WIT, clamping technique (yes/no), % perioperative
complications, and surgical margin status (positive surgical
margin [PSM]). Oncologic outcomes included final histol-
ogy, staging (according to the tumor, node, metastasis
[TNM] classification system), local tumor recurrence (recur-
rence-free survival [RFS]), and overall survival (OS). Long-
term functional outcomes consist of new-onset CKD stage 4,
5, defined as end-stage renal disease (ESRD), at the last
recorded follow-up.
Baseline eGFR was calculated by the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula to
determine baseline renal function [11]. The first postopera-
tive eGFR was considered eGFR at discharge. The DeGFR was
estimated for evaluating the impact of the surgical proce-
dure on renal function. Baseline and postoperative CKD
stages were assessed according to KDIGO International
Guidelines [12]. Complications within 30 d after surgery
were recorded and graded according to the Clavien-Dindo
classification [13]. Major complications were categorized as
Clavien grade III or higher according to European Associa-
tion of Urology guidelines [14]. Tumor size was selected by
the largest dimension with the RENAL nephrometry scoring
system to classify the complexity of tumor [15]. PSMs were
defined by the presence of tumor cells at the level of
parenchyma excision surface [16]. All patients with PSMs
were followed up with thoracoabdominal computed
tomography scan every 6 mo during the 1 st year after
treatment and every 12 mo thereafter.
Data were used to outline two binary variables for the
achievement of MIC (defined as the contemporary absence
of negative margins, ischemia time <20 min, absence of
major complications [Clavien-Dindo 3]) and trifecta
(defined as the contemporary absence of PSMs, major
complications, and 30% postoperative eGFR reduction)
[6,9].pact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.
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whole cohort and in a subgroup cohort of patients receiving
off-clamp RAPN (ocRAPN). Descriptive analyses were used.
Frequencies and proportions were reported for categorical
variables, while means and standard deviations were
reported for continuously coded variables. OS, RFS, and
ESRD probabilities were computed by Kaplan-Meier curves,
and compared for MIC and trifecta achievement with the
log-rank test, respectively.
Univariable and multivariable Cox regression analyses
were performed to identify predictors of OS, RFS, and ESRD.
For all analyses, two-sided p < 0.05 was considered signifi-
cant. Statistical analysis was carried out using the Statistical
Package for Social Sciences (SPSS) software v.26.0 (IBM
Corp, Armonk, NY, USA).
3. Results
Descriptive statistics of the study population are shown in
Table 1 and Supplementary Table 1. The mean patient age
was 61 yr (range 22–90 yr). The mean clinical tumor size
was 4.7 cm (range 1–20 cm), while the mean RENAL scoreTable 1 – Patients’ demographic and preoperative characteristics accor
Variable Overall
(n = 1807)
Age (yr), mean  SD 61.1  11.8 
Male gender, n (%) 1211 (67) 
BMI (kg/m2), mean  SD 28  5.9 
ASA score, n (%)
1–2 1217 (67.3) 
3–4 590 (32.7) 
Center, n (%)
Careggi 492 (27.2) 
IRE 449 (24.8) 
OLV 421 (23.3) 
Cleveland Clinic 133 (7.4) 
San Luigi Gonzaga 133 (7.4) 
HSR 96 (5.3) 
Brescia 62 (3.4) 
VCU 21 (1.2) 
Clinical tumor size (cm), mean  SD 4.7  3.2 
RENAL score, n (%)
4 260 (14.4) 
5 325 (18) 
6 289 (16) 
7 271 (15) 
8 252 (13.9) 
9 217 (12) 
10 126 (7) 
11 57 (3.2) 
12 10 (0.6) 
Off-clamp approach, n (%) 654 (36.2) 
Preoperative GFR (ml/min/1.73 m2), mean  SD 88.2  25.9 
Baseline CKD, n (%)
1 833 (46.1) 
2 764 (42.3) 
3a 128 (7.1) 
3b 55 (3) 
4 23 (1.3) 
5 4 (0.2) 
ASA = American Society of Anesthesiologists; BMI = body mass index; CKD = chro
complications, score; SD = standard deviation.
Data are reported as mean (SD).
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RENAL score of 4–6, 740 (41%) had a RENAL score of 7–9, and
193 (10.7%) had a RENAL score of >9. The Mean preoperative
eGFR was 88.2 ml/min (range 6–156). At baseline,
1597 patients (88.4%) had CKD stage 1–2, 183 (10.1%) had
CKD stage 3a-3b, and 27 (1.5%) had ESRD.
Perioperative and pathologic outcomes are summarized in
Table 2 and Supplementary Table 2. The Mean WIT was 11.9
min (range 0–59 min). A total of 368 patients (20.4%) had a
WIT of >20 min, while 654 (36.2%) underwent a clampless
procedure. PSMs were observed in 60 patients (3.3%). The
overall complication rate was 12.6%. More in detail, the
distribution by Clavien grade was 203 grade I–II complica-
tions (11.2%) and 20 grade III–V complications (1.1%). At final
pathology, a benign tumor was described in 251 cases (13.8%).
At a mean follow-up of 30.7 mo (range 0–107 mo), 80 patients
(4.4%) developed a local recurrence (Table 3).
Overall, MIC was achieved in 71.1%, with 1355 patients
(75%) achieving a WIT of <20 min. The trifecta rate was
82.6%, with 1592 patients (88.1%) achieving a DeGFR of
30%. In the off-clamp subgroup, the MIC was 95.6%
(n = 625), with seven patients (1%) reporting no majording to MIC and trifecta achievement.
MIC
(n = 1285; 71.1)
Trifecta
(n = 1492; 82.6)
61.2  11.7 60.6  11.9
855 (66.5) 995 (66.7)
27.6  5.5 27.7  5.6
918 (71.4) 1019 (68.3)
367 (28.6) 473 (31.7)
243 (18.9) 421 (28.2)
428 (33.3) 347 (23.3)
315 (24.5) 363 (24.3)
56 (4.4) 104 (7)
103 (8) 105 (7)
83 (6.5) 81 (5.4)
37 (2.9) 51 (3.4)
20 (1.6) 20 (1.3)
4.7  3.4 4.5  3.2
216 (16.8) 227 (15.2)
260 (20.2) 271 (18.2)
225 (17.5) 246 (16.5)
186 (14.5) 232 (15.5)
158 (12.3) 193 (12.9)
124 (9.6) 179 (12)
69 (5.4) 93 (6.2)
38 (3) 42 (2.8)
9 (0.7) 9 (0.6)
625 (48.6) 534 (35.8)
89.9  25.4 88.9  25.5
599 (46.6) 700 (46.9)
563 (43.8) 629 (42.2)
77 (6) 102 (6.8)
27 (2.1) 37 (2.5)
16 (1.2) 20 (1.3)
3 (0.2) 4 (0.3)
nic kidney disease; GFR = glomerular filtration rate; MIC = margin, ischemia,
pact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.




(n = 1285; 71.1)
Trifecta
(n = 1492; 82.6)
PSM, n (%) 60 (3.3) 0 0
Overall complications (any), n (%) 229 (12.6) 124 (9.6) 168 (11.2)
Perioperative Clavien grade, n (%)
1 Ileus (56), wound dehiscence (15),
fever (9), colitis (4), vomit (6)
Ileus (25), wound dehiscence (9),
fever (5) vomit (3),
Ileus (45), wound dehiscence (10),
fever (9), vomit (3), colitis (4)
2 Anemia (115), pneumonia (4) Anemia (80), pneumonia (2) Anemia (93), pneumonia (4)
3 Urinary leakage (10), severe active
bleeding (7), cardiac arrhythmia (1)
– –
4 Acute myocardial infarction (1),
atrial fibrillation (1)
– –
5 – – –
EBL (ml), mean  SD 172.2  213.4 130  128.09 158.3  183.7
WIT (min)a, mean  SD 11.99  11.1a 7.05  7.3a 11.6  10.6a
OT (min), mean  SD 160.5  60.9 148.6  53.2 157.4  54.8
LOS (d), mean  SD 4.6  2.1 4.3  1.7 4.4  2.02
Postoperative eGFR (ml/min/1.73 m2),
mean  SD
80.14  27.31 82  26.8 84.4  25.7
DeGFR, mean  SD –8.84  21.25 –7.9  20.7 –4.19  17.80
Benign histology, n (%) 251 (13.8) 205 (16) 218 (14.6)
pT stage, n (%)
pT1a 990 (54.8) 736(57.3) 844 (56.6)
pT1b 382 (21.1) 238 (18.5) 303 (20.3)
pT2a 35 (1.9) 25 (1.9) 26 (1.7)
pT2b 11 (0.6) 10 (0.8) 8 (0.5)
pT3a 138 (7.6) 71 (5.5) 93 (6.2)
EBL = estimated blood loss; eGFR = estimated glomerular filtration rate; LOS = length of hospital stay; MIC = margin, ischemia, complications, score; OT =
operative time; PSM = positive surgical margin; RAPN = robotic-assisted partial nephrectomy; SD = standard deviation; WIT = warm ischemia time.
Data are reported as mean (SD).
a Data refer to the on-clamp RAPN subgroup.
Table 3 – Oncologic and functional outcomes according to MIC and trifecta achievement.
Variable Overall (n = 1807) MIC (n = 1285; 71.1%) Trifecta (n = 1492; 82.6%)
Follow-up (mo), mean  SD 30.7  24.08 31.78  23.5 31.97  24.3
OS, % (n deaths) 97.7 (42) 98.3 (22) 98 (31)
RFS, % (n recurrences) 95.6 (80) 95.6 (57) 96 (61)
New-onset CKD 3a, n (%) 181 (10) 109 (8.4) 134 (8.9)
New-onset CKD 3b, n (%) 67 (3.7) 24 (1.9) 40 (2.7)
New-onset CKD 4, 5, n (%) 32 (1.7) 12 (0.93) 16 (1)
CKD = chronic kidney disease; MIC = margin, ischemia, complications, score; OS = overall survival; RFS = recurrence-free survival.
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margins, while the trifecta rate was 81.6%, with 562 patients
(85.9%) achieving a DeGFR of 30% (Supplementary
Tables 1–3).
Overall, at a mean follow-up of 30.7 mo (range 0–107
mo), 181 patients (10%) developed a new-onset CKD stage
3a, 67 (3.7%) developed a stage 3b, and 32 (1.7%) developed a
stage 4–5 (Table 3 and Supplementary Table 3).
On Kaplan-Meier analysis, patients achieving MIC and
trifecta displayed significantly higher OS (p = 0.004 and p =
0.014, respectively; Fig. 1) and lower ESRD development
probabilities (both p < 0.001; Fig. 2). RFS probability was
predicted by trifecta achievement, and not by MIC (p =
0.009 vs p = 0.355; Fig. 3).
At multivariable Cox regression analysis, age (hazard
ratio [HR] 1.04, 95% confidence interval [CI] 1.01–1.08; p =
0.017), ASA score (HR 3.06, 95% CI 1.47–6.37; p = 0.003),Please cite this article in press as: Anceschi U, et al. Head to Head Im
Trifecta Score on Oncologic and Functional Outcomes After Robotic
Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020.06.021baseline eGFR (HR 0.98, 95% CI 0.97–0.99; p = 0.009), and
trifecta achievement (HR 0.4, 95% CI 0.18–0.86; p = 0.019)
were all independent predictors of OS (Table 4). RENAL
score (HR 2.10; 95% CI 1.08–4.10) and baseline eGFR (HR
0.98; 95% CI 0.97–0.99) were the only independent predic-
tors of RFS (Table 5). With regard to functional outcomes,
ASA score (HR 2.89, 95% CI 1.11–7.25; p = 0.023), baseline
eGFR (HR 0.93, 95% CI 0.91–0.95; p < 0.001), and trifecta (HR
0.32, 95% CI 0.15–0.72; p = 0.005) were independent pre-
dictors of new-onset ESRD (Table 6).
4. Discussion
An ideal trifecta for RAPN should offer more inclusive and
achievable criteria without compromising a comprehensive
assessment of oncologic and functional results [17]. How-
ever, due to the complexity of surgical factors involved, bothpact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.
Fig. 1 – Kaplan-Meier curves showing OS probabilities for patients achieving MIC and trifecta or not. MIC = margin, ischemia, complications, score; OS
= overall survival; SE = standard error.
Fig. 2 – Kaplan-Meier curves showing ESRD (CKD 4, 5) probabilities for patients achieving MIC and trifecta or not. CKD = chronic kidney disease; ESRD
= end-stage renal disease; MIC = margin, ischemia, complications, score.
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WIT as the major determinant of renal function [18,19]. The
lack of adjustment for the real amount of parenchyma
preserved, tumor size, and baseline eGFR represent major
drawbacks when assessing the role of WIT in predicting
functional outcomes of RAPN [20]. Furthermore, the MIC
score does not account for any renal damage that may
potentially accrue during off-clamp procedures [21,22]. Ini-
tially, Hung et al [1] proposed a trifecta adopting predicted
postoperative eGFR by the percent of kidney tissue pre-
served instead of WIT, but the subjective and complex
assessment method of criteria precluded its adoption in
clinical practice [2]. Recently, Brassetti et al [9,10] describedPlease cite this article in press as: Anceschi U, et al. Head to Head Im
Trifecta Score on Oncologic and Functional Outcomes After Robotic
Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020.06.021a novel trifecta supporting DeGFR as a potential marker of
AKI.
Any trifecta is initially conceived to provide a compre-
hensive measure of perioperative outcomes. The use of a
WIT threshold, for instance, does not apply properly to a
pure ocRAPN cohort: in fact, the overall increased number
of patients achieving trifecta (n = 1492) compared with MIC
(n = 1285) may be explained by the more flexible criteria
used for AKI definition. Conversely, trifecta provided a
stricter selection in patients, which may improperly be
considered with MIC score achieving no ischemia by defi-
nition as in the off-clamp subgroup (81.8% vs 95.6%; Sup-
plementary Table 1).pact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.
Fig. 3 – Kaplan-Meier curves showing RFS probabilities for patients achieving MIC and trifecta or not. MIC = margin, ischemia, complications, score;
RFS = recurrence-free survival.
Table 4 – Univariable and multivariable Cox regression analysis to identify predictors of OS.
Variable Univariable analysis Multivariable analysis (MIC) Multivariable analysis (trifecta)
HR 95% CI HR 95% CI HR 95% CI
Lower Higher p value Lower Higher p value Lower Higher p value
Age 1.05 1.02 1.08 0.001 1.05 1.01 1.08 0.008 1.04 1.01 1.08 0.017
Gender 1.23 0.63 2.41 0.533 – – – –
ASA score
1–2 4.6 2.42 8.75 <0.001 3.04 1.46 6.33 0.003 3.06 1.47 6.37 0.003
3–4
BMI 1.04 1.01 1.09 0.049 1.02 0.97 1.07 0.37 1.02 0.97 1.07 0.35
Tumor size 1 0.99 1.01 0.659 – – – – – – – –
RENAL (4–9 vs 9–12) 1.28 0.60 2.68 0.515 – – – – – – – –
pT stage 1.04 0.36 3.01 0.940 – – – – – – – –
Benign/malignant 0.48 0.11 2 0.314 – – – – – – – –
Preoperative eGFR 0.97 0.96 0.99 <0.001 0.98 0.97 0.99 0.016 0.98 0.97 0.99 0.009
MIC 0.42 0.22 0.77 0.005 0.71 0.37 1.36 0.304 – – – –
Trifecta 0.43 0.21 0.86 0.017 – – – – 0.4 0.18 0.86 0.019
Hurrell’s C-index
Full model 0.82 0.8
Restricted 0.78 0.84
ASA = American Society of Anesthesiologists; BMI = body mass index; CI = confidence interval; eGFR = estimated glomerular filtration rate; HR = hazard ratio;
MIC = margin, ischemia, complications, score; OS = overall survival.
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predict maintenance of favorable long-term outcomes. Con-
sequently, we aimed at assessing whether MIC and trifecta
“stand the test of time” by analyzing the role of both MIC
and trifecta in predicting main clinical outcomes, namely,
OS, RFS, and ESRD probabilities. Our analysis showed inter-
esting findings. At multivariable analysis, compared with
MIC, trifecta was an independent predictor of both OS (p =
0.019) and ESRD (p = 0.005). Since postoperative eGFR after
RAPN has recently been identified as a more significant
predictor of long-term survival than WIT, it is reasonable to
assume that incorporation of perioperative eGFR variationsPlease cite this article in press as: Anceschi U, et al. Head to Head Im
Trifecta Score on Oncologic and Functional Outcomes After Robotic
Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020.06.021in our novel criteria turned into superiority of trifecta over
MIC in predicting significant renal impairment and overall
mortality by implication [5].
It is noteworthy that at univariable analysis, trifecta
achievement significantly predicted RFS (p = 0.01), while
MIC did not (p = 0.357). This finding may be explained by the
slightly different distribution of patients who achieved
trifecta compared with MIC in terms of tumor complexity
(RENAL score >921.6% vs 18.7%) and pT stage (pT 2b 6.7%
vs 6.3%), considering the negligible overall PSM rates
observed (3.3%). We are aware that the achievement of
negative surgical margins may certainly not replace long-pact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.
Table 5 – Univariable and multivariable Cox regression analysis to identify predictors of RFS.
Variable Univariable analysis Multivariable analysis (TRIFECTA)
HR 95% CI HR 95% CI
Lower Higher p value Lower Higher p value
Age 1.01 0.99 1.03 0.244 – – – –
Gender 1.53 0.91 2.57 0.10 – – – –
ASA score
1–2 1.50 0.93 2.45 0.09 – – – –
3–4
BMI 0.93 0.86 1.01 0.109 – – – –
RENAL (4–9 vs 9–12) 3.34 1.85 6.01 <0.001 2.10 1.08 4.10 0.029
pT stage 2.38 0.97 5.84 <0.001 1.76 0.47 6.57 0.05
Benign/malignant 0.44 0.16 1.20 0.111 – – – –
Preoperative eGFR 0.98 0.97 0.99 <0.001 0.98 0.97 0.99 0.023
MIC 0.79 0.48 1.29 0.357 – – – –
Trifecta 0.50 0.29 0.84 0.01 0.66 0.32 1.36 0.268
ASA = American Society of Anesthesiologists; BMI = body mass index; CI = confidence interval; eGFR = estimated glomerular filtration rate; HR = hazard ratio;
MIC = margin, ischemia, complications, score; RFS = recurrence-free survival.
Table 6 – Univariable and multivariable Cox regression analysis to identify predictors of newly onset of ESRD.
Variable Univariable analysis Multivariable analysis (MIC) Multivariable analysis (trifecta)
HR 95% CI HR 95% CI HR 95% CI
Lower Higher p value Lower Higher p value Lower Higher p value
Age 1.06 1.02 1.10 <0.001 1.02 0.98 1.06 0.161 1.02 0.98 1.046 0.249
Gender 1.49 0.67 3.33 0.322 – – – – – – – –
ASA score
1–2 8.7 3.92 19.6 <0.001 2.78 1.11 6.98 0.02 2.89 1.11 7.25 0.023
3–4
BMI 1.06 1.01 1.11 0.016 1 0.94 1.08 0.768 1 0.93 1.07 0.952
RENAL (4–9 vs 9–12) 2.69 1.28 5.64 0.009 0.20 0.05 1.63 0.160 0.22 0.04 1.19 0.079
Preoperative eGFR 0.92 0.91 0.94 <0.001 0.92 0.90 0.94 <0.001 0.93 0.91 0.95 <0.001
MIC 0.19 0.09 0.39 <0.001 0.45 0.17 1.15 0.09 – – – –




Restricted model 0.94 0.95
ASA = American Society of Anesthesiologists; BMI = body mass index; CI = confidence interval; eGFR = estimated glomerular filtration rate; ESRD = end-stage
renal disease; HR = hazard ratio; MIC = margin, ischemia, complications, score.
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EUF-956; No. of Pages 9term oncologic outcomes of RAPN [23]. However, as local
tumor recurrence is associated with multiple factors such as
adverse pathologic features (renal hilum/sinus invasion)
and tumor upstaging, it would have been interesting to
adjust the model for these variables, but unfortunately, they
were unavailable in our dataset [24]. Furthermore, the use
of a broad definition of local recurrence (such as any new
mass in the ipsilateral kidney following partial nephrec-
tomy) could potentially have captured sporadic or meta-
chronous recurrences and does not necessarily reflect a
matter of surgical quality [25]. Finally, in our study, preop-
erative eGFR and RENAL score were also independent pre-
dictors of RFS (p = 0.023 and p = 0.029; respectively). These
findings are in line with current evidence, suggesting that
higher nephrometry scores are associated with shorter
progression-free survival and higher recurrence rates as
the oncologic risk of CKD in patients with kidney cancerPlease cite this article in press as: Anceschi U, et al. Head to Head Im
Trifecta Score on Oncologic and Functional Outcomes After Robotic
Eur Urol Focus (2020), https://doi.org/10.1016/j.euf.2020.06.021is increased when the preoperative eGFR is significantly
compromised [26,27].
Our study is not devoid of limitations. First of all, it is a
retrospective analysis of data. In addition, multicenter data-
bases provide a large cohort and thus a large amount of data,
but undoubtedly imply different caseloads and different
techniques, regardless of the tertiary care nature of all
involved centers. Besides, we were unable to adjust regres-
sion models for all potential confounders: for instance,
comorbidities were available for all cases only as ASA scores,
tumor resection strategies were not available for all cases,
and a rigorous measurement of preserved parenchymal
volume preserved after surgery was not performed. More-
over, the role of medical comorbidities, namely, diabetes
and hypertension, may play a role in long-term renal func-
tion that we were unable to account for. Eventually, our data
require prospective external validation to confirm thepact of Margin, Ischemia, Complications, Score Versus a Novel
-assisted Partial Nephrectomy: Results of a Multicenter Series.
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EUF-956; No. of Pages 9strong predictive role of this novel trifecta in main long-
term outcomes [28].
Despite these limitations, this trifecta showed interest-
ing features such as a user-friendly profile, broader appli-
cation for different surgical techniques of RAPN, and its
independent predictive role in both OS and risk of develop-
ing a significant worsening of renal function in the long run.
Compared with MIC, it could safely be adopted in clinical
practice to help urologists in the assessment and compari-
son of RAPN outcomes rather than as a reliable, predictive
tool of survival and ESRD.
5. Conclusions
Trifecta, initially described as a comprehensive measure of
surgical outcomes, needs to stand the test of time. Our
trifecta outperformed MIC in terms of the ability to predict
oncologic outcomes and ESRD after RAPN, and proved to be
an independent predictor of long-term OS and ESRD devel-
opment probabilities. This new and easy clinical tool repre-
sents a comprehensive marker of surgical quality and a
reliable method for estimating survival and development
of ESRD during follow-up.
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